Zirconium-89 Radiolabeled Hollow Ferulic Acid Nanostructure for PET Imaging Guided Acute Kidney Injury Therapy

Tuanwei Sun,Zachary Rosenkrans,Dawei Jiang,Dalong Ni,Carolina Ferreira,Weiyu Chen,Jonathan Engle,Weibo Cai
2019-01-01
Journal of Nuclear Medicine
Abstract:416 Objectives: Acute kidney injury (AKI) is a common reactive oxygen species (ROS)-related renal disease, which is of high morbidity and mortality. Ferulic acid (FA) is a natural phenolic acid with strong antioxidative and cytoprotective activities. Although FA has been studied to protect AKI through intraperitoneal injection or gavage, the low bioavailability of FA has limited the therapeutic effect. To the best of our knowledge, a FA-based nanostructure for AKI therapy has not been reported. Our goal is to construct a novel FA nanostructure to rapidly accumulate in kidney and treat AKI by eliminating ROS. Methods: Hollow FA nanoparticles (HFAN) were prepared via a hydrothermal treatment and further treated with PEGylation (HFAN-PEG). HFAN-PEG was radiolabeled with Zr-89 (half-life: 78.4 h) using the chelator DFO (89Zr-DFO-HFAN-PEG). The biodistribution and renal accumulation of HFAN-PEG in healthy and AKI mice were evaluated using positron emission tomography (PET) imaging. The AKI model was induced by intramuscularly injecting 50% glycerol into the hind limbs (8mL/kg). HFAN-PEG was intravenously injected for AKI therapy with different doses. PBS and FA were used as the negative control and positive control, respectively. The therapeutic effect was evaluated by blood levels of blood urea nitrogen and creatinine, and kidney tissue staining. Results: The HFAN-PEG showed good ROS-scavenging activities for free radical, •OH and O2•‒. Importantly, PET imaging revealed that HFAN-PEG rapidly entered the kidneys of mice (27.1 ± 2.0 %ID/g at 10 min post-injection and 42.6 ± 5.7 %ID/g at 1 h post-injection; n=3) and accumulated in kidneys up to 72 h (12.7 ± 1.8 %ID/g; n=3) after intravenous injection. Furthermore, HFAN-PEG was found to be therapeutically effective for AKI at the dose of 50 µg FA per mouse and to significantly alleviate AKI at the dose of 10 µg FA per mouse, which was confirmed by serum tests and kidney tissue staining. More interestingly, compared with HFAN-PEG therapy group, the FA chemical showed a much worse therapeutic effect at a dose of 50 µg FA per mouse. Conclusion: With the multi-antioxidative activities and high renal accumulation, HFAN-PEG exhibited a good protective effect against AKI in mice, which endows HFAN-PEG the potential for the treatment of AKI patients.
What problem does this paper attempt to address?